Price (delayed)
$1.855
Market cap
$50.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.5
Enterprise value
-$102.44M
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Building on more than a decade of ...
Highlights
The EPS has soared by 74% year-on-year and by 50% since the previous quarter
ANRO's quick ratio is up by 30% since the previous quarter and by 15% year-on-year
The company's net income has shrunk by 69% YoY and by 7% QoQ
The debt has surged by 63% year-on-year
Key stats
What are the main financial stats of ANRO
MarketValuationsEarnings
Shares outstanding
27.07M
Market cap
$50.22M
Enterprise value
-$102.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.33
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$68.61M
Net income
-$61.43M
EBIT
-$60.06M
EBITDA
-$59.22M
Free cash flow
-$49.5M
Per shareBalance sheetLiquidity
EPS
-$2.5
EPS diluted
-$2.5
Free cash flow per share
-$2.01
Book value per share
$5.62
Revenue per share
$0
TBVPS
$7.22
Total assets
$177.54M
Total liabilities
$26.08M
Debt
$16.07M
Equity
$151.46M
Working capital
$159.33M
Debt to equity
0.11
Current ratio
16.92
Quick ratio
16.86
Net debt/EBITDA
2.58
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-31.6%
Return on equity
-35.6%
Return on invested capital
-662.2%
Return on capital employed
-35.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANRO stock price
How has the Alto Neuroscience stock price performed over time
Intraday
-9.51%
1 week
-23.03%
1 month
-40.92%
1 year
-86.92%
YTD
-56.15%
QTD
-14.12%
Financial performance
How have Alto Neuroscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.61M
Net income
-$61.43M
Gross margin
N/A
Net margin
N/A
ANRO financials
Alto Neuroscience's operating income has shrunk by 81% YoY and by 8% QoQ
The company's net income has shrunk by 69% YoY and by 7% QoQ
Growth
What is Alto Neuroscience's growth rate over time
ANRO growth chart
Valuation
What is Alto Neuroscience stock price valuation
P/E
N/A
P/B
0.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has soared by 74% year-on-year and by 50% since the previous quarter
Price to book (P/B)
The price to book (P/B) is 77% less than the last 4 quarters average of 1.6
ANRO's equity is down by 8% QoQ
Price to sales (P/S)
Efficiency
How efficient is Alto Neuroscience business performance
The return on assets is up by 40% year-on-year and by 6% since the previous quarter
Alto Neuroscience's ROIC has decreased by 40% YoY but it has increased by 12% from the previous quarter
The ROE has increased by 28% QoQ
Dividends
What is ANRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANRO.
Financial health
How did Alto Neuroscience financials performed over time
Assets vs liabilities
ANRO's total assets has surged by 105% year-on-year but it is down by 7% since the previous quarter
The total liabilities has soared by 55% YoY
Debt vs equity
The debt is 89% smaller than the equity
ANRO's debt to equity has soared by 179% YoY and by 10% from the previous quarter
The debt has surged by 63% year-on-year
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.